JPH07502727A - 接着分子に対する抗体を用いた同種移植片拒絶の防止 - Google Patents

接着分子に対する抗体を用いた同種移植片拒絶の防止

Info

Publication number
JPH07502727A
JPH07502727A JP5507007A JP50700793A JPH07502727A JP H07502727 A JPH07502727 A JP H07502727A JP 5507007 A JP5507007 A JP 5507007A JP 50700793 A JP50700793 A JP 50700793A JP H07502727 A JPH07502727 A JP H07502727A
Authority
JP
Japan
Prior art keywords
receptor
antibody
ligand
specific
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5507007A
Other languages
English (en)
Japanese (ja)
Inventor
イソベ　ミツアキ
Original Assignee
ザ・ジエネラル・ホスピタル・コーポレーシヨン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジエネラル・ホスピタル・コーポレーシヨン filed Critical ザ・ジエネラル・ホスピタル・コーポレーシヨン
Publication of JPH07502727A publication Critical patent/JPH07502727A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP5507007A 1991-10-01 1992-09-29 接着分子に対する抗体を用いた同種移植片拒絶の防止 Pending JPH07502727A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76804491A 1991-10-01 1991-10-01
US768,044 1991-10-01
PCT/US1992/008279 WO1993006864A1 (en) 1991-10-01 1992-09-29 Preventing allograft rejection with antibodies to adhesion molecules

Publications (1)

Publication Number Publication Date
JPH07502727A true JPH07502727A (ja) 1995-03-23

Family

ID=25081356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5507007A Pending JPH07502727A (ja) 1991-10-01 1992-09-29 接着分子に対する抗体を用いた同種移植片拒絶の防止

Country Status (8)

Country Link
EP (1) EP0610298A1 (es)
JP (1) JPH07502727A (es)
AU (1) AU667487B2 (es)
CA (1) CA2120500A1 (es)
HU (1) HUT69725A (es)
MX (1) MX9205637A (es)
WO (1) WO1993006864A1 (es)
ZA (1) ZA927503B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
WO1993015764A1 (en) * 1992-02-12 1993-08-19 Biogen, Inc. Treatment for inflammatory bowel disease
DE69315847T2 (de) * 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
US5817515A (en) * 1993-12-23 1998-10-06 Icos Corporation Human B2 integrin alpha subunit antibodies
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
CA2454618C (en) 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
WO2005115436A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
AU2005254980A1 (en) 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
EP0365837B1 (en) * 1988-09-28 1995-08-02 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
JPH04501565A (ja) * 1988-11-14 1992-03-19 ブリガム・アンド・ウイメンズ・ホスピタル Ｅｌａｍ―１に特異的な抗体およびその用途
EP0387701B1 (en) * 1989-03-09 1992-08-12 Boehringer Ingelheim Pharmaceuticals Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
WO1990013316A1 (en) * 1989-04-28 1990-11-15 Baylor College Of Medicine Dissemination of hiv-1 infected cells
US5011778A (en) * 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method

Also Published As

Publication number Publication date
MX9205637A (es) 1993-05-01
AU2782992A (en) 1993-05-03
EP0610298A1 (en) 1994-08-17
HUT69725A (en) 1995-09-28
AU667487B2 (en) 1996-03-28
CA2120500A1 (en) 1993-04-15
WO1993006864A1 (en) 1993-04-15
ZA927503B (en) 1993-05-03
HU9400930D0 (en) 1994-06-28

Similar Documents

Publication Publication Date Title
AU656150B2 (en) Methods for inhibiting rejection of transplanted tissue
US7638121B2 (en) Methods for human allografting
JP2002502824A (ja) 同種移植における補刺激遮断および混合キメラ現象
Frumento et al. Immunotherapy for type 1 diabetes
JPH08500826A (ja) Ｌｆａ−１仲介疾患を処置する方法
CN1261284A (zh) 应用cd40∶cd154结合阻断物预防逆适应性免疫应答,特别是移植物排斥反应
JPH07502727A (ja) 接着分子に対する抗体を用いた同種移植片拒絶の防止
US20090035257A1 (en) Devices, compositions and methods for the protection and repair of cells and tissues
AU7956798A (en) Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
Waegell et al. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection
Guo et al. Long‐term survival of intestinal allografts induced by costimulation blockade, busulfan and donor bone marrow infusion
US10086070B2 (en) Combined therapy of alpha-1-antitrypsin and temporal T-cell depletion for preventing graft rejection
JP3702330B2 (ja) 移植の拒絶を防止する方法
Xu et al. A delay in bone marrow transplantation after partial conditioning improves engraftment1
JPH06298654A (ja) 抗原特異的免疫抑制剤
EP0219716A2 (en) Immunosuppressive agent
JP2003089656A (ja) 移植による免疫反応抑制剤
Willetts Novel Immunosuppressants in Small Intestinal Transplantation
JPH09500364A (ja) 異種移植片の胸腺
Granger et al. Section IV-Transplantation and Immunology
Stuart THE CLINICAL PROBLEM
Graham et al. THE ROLE OF NATURAL KILLER CELLS IN LYMPHOCYTIC CHORIOMENINGITIS VIRUS (LCMV) INDUCED CORONARY ALLOGRAFT VASCULOPATHY (CAV): 744
van Ree et al. CAN AND ANTIBODIES CONCURRENT ORAL SESSION 57: CIRCULATING MARKERS OF ENDOTHELIAL DYSFUNCTION INTERACT WITH PROTEINURIA IN PREDICTING MORTALITY IN RENAL TRANSPLANT RECIPIENTS: 746
WO1998056823A1 (en) Induction of immune tolerance by immunotoxin